A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer Article

Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu et al. (2022). A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer . CANCER CHEMOTHERAPY AND PHARMACOLOGY, 89(5), 721-735. 10.1007/s00280-022-04430-6

Open Access

cited authors

  • Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Hendrickson, Andrea E Wahner; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji, Jiuping; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H

sustainable development goals

authors

publication date

  • May 1, 2022

published in

keywords

  • BRCA1
  • BRCA2
  • CARBOPLATIN
  • CARCINOMA
  • COMBINATION
  • DNA damage
  • DNA-REPAIR
  • DOUBLE-BLIND
  • GERMLINE BRCA1
  • Life Sciences & Biomedicine
  • MUTATION
  • OLAPARIB
  • Oncology
  • Ovarian cancer
  • PARP INHIBITOR VELIPARIB
  • PARP inhibitor
  • POLY(ADP-RIBOSE) POLYMERASE INHIBITOR
  • Pharmacodynamics
  • Pharmacokinetics
  • Pharmacology & Pharmacy
  • Phase I
  • Science & Technology
  • Solid tumors
  • Triple-negative breast cancer
  • Veliparib

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 721

end page

  • 735

volume

  • 89

issue

  • 5